<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630760</url>
  </required_header>
  <id_info>
    <org_study_id>0C-07-6</org_study_id>
    <nct_id>NCT00630760</nct_id>
  </id_info>
  <brief_title>Oral NRX 194204 in Patients With Refractory Malignancies</brief_title>
  <official_title>A Multiple-Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Refractory Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I study will determine the safety profile of NRX 194204 on this schedule; it will
      evaluate the pharmacokinetic profile of NRX 194204 in cancer patients; and will investigate
      anti-tumor activity as manifested by standard response criteria, or by tumor markers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor withdrew study. Accrual not completed
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine MTD</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Day 29 and then every 56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Refractory Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRX 194204 capsules in escalating doses, starting at 3mg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRX 194204</intervention_name>
    <description>NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent.

          -  Histologically confirmed cancer refractory to conventional therapy or refractory
             cancer for which there is no known effective or standard therapy.

          -  Measurable or non-measurable disease.

          -  Male or female, 18 to 75 years of age, inclusive.

          -  ECOG Performance Status 0-2

          -  Life expectancy greater than 24 weeks.

          -  Able to swallow the oral capsule form of the drug.

          -  Hematology: Hemoglobin greater than or equal to 8.5; Platelets greater than or equal
             to100,000; Neutrophils greater than or equal to 1500

          -  PT and PTT within normal limits, except for patients receiving oral Vitamin K
             antagonist for thromboembolic prophylaxis, in whom an INR less than 2 is allowable.

          -  Biochemistry: Total bilirubin less than or equal to 1.5 x ULN; AST/ALT less than or
             equal to 3.0 x ULN; Serum creatinine less than or equal to 2.0 mg/dl; Serum calcium
             less than or equal 11.5 mg/dl; Fasting serum triglycerides less than or equal 2.5 x
             ULN

          -  Endocrine: Thyroid stimulating hormone (TSH)within institutional normal limits
             (typically greater than 0.5 mU/L and less than 5.5 mU/L)

          -  Negative urine pregnancy test for women of child-bearing potential at screening and on
             Day 0, and agreement to use two reliable forms of contraception during therapy and for
             1 month following discontinuation of therapy unless abstinence is the chosen birth
             control method.

          -  Able to follow study instructions, accessible for treatment and follow-up, and likely
             to complete all study requirements

        Exclusion Criteria:

          -  Major surgery within previous 4 weeks; large field radiation therapy or chemotherapy
             ,including investigational agents or participation in another clinical study within
             previous 3 weeks; mitomycin C or nitrosoureas within 6 weeks. In all instances
             patients must have fully recovered from acute toxicities related to prior therapies.

          -  Systemic retinoid therapy, or large doses of Vitamin A during previous 4 weeks.

          -  Patients with any prior or current history of thyroid disease, with any history of
             pituitary disease, or with any history of prior or current treatment with thyroid
             replacement hormone.

          -  Primary brain tumors, active brain metastasis including progression from last scan or
             evidence of cerebral edema, or clinical symptoms of brain metastasis. Patients with
             prior history of brain metastasis must have brain imaging performed and be found to be
             stable or improving over a minimum interval of 8 weeks.

          -  Requirement for steroids. Note:Patients taking stable dosages of GnRH analogues or
             Megace for at least the previous 3 months will be allowed into the study.

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 21 days of entry into this study.

          -  Prior enrollment in the study (Quest 194204-101-00); patients may only enroll once and
             be treated only at one dose level.

          -  Known sensitivity to any of the ingredients in the study medication.

          -  Known HIV-positive patients.

          -  Females who are pregnant, nursing, or planning a pregnancy.

          -  History of gastrointestinal disorders (medical disorders or extensive surgery) which
             may interfere with absorption of study medication.

          -  Clinically significant abnormalities on screening ECG (QTc greater than 480 msec).

          -  Patient has a condition or is in a situation that, in the investigator's opinion, may
             put him/her at significant risk, may confound the study results, or may interfere
             significantly with his/her participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

